Chinook Therapeutics, Inc.
113 articles about Chinook Therapeutics, Inc.
-
Chinook Therapeutics Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
11/30/2020
Chinook Therapeutics, Inc. (NASDAQ: KDNY), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that the Compensation Committee of the Company’s Board of Directors approved a new employment inducement grant of stock
-
Chinook Therapeutics to Present at Upcoming Investor Conferences
11/18/2020
Chinook Therapeutics, Inc. (NASDAQ: KDNY), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that Chinook management is scheduled to participate in fireside chats at the following upcoming virtual investor conferences
-
Chinook Therapeutics Announces Appointment of Eric Bjerkholt as Chief Financial Officer
11/10/2020
Chinook Therapeutics, Inc. (NASDAQ: KDNY), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced the appointment of Eric Bjerkholt as Chief Financial Officer (CFO).
-
Chinook Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update
11/5/2020
Chinook Therapeutics, Inc. (NASDAQ: KDNY), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced third quarter 2020 financial results and provided a business update.
-
Chinook Therapeutics Presents Data Across Kidney Disease Pipeline During the American Society of Nephrology (ASN) Kidney Week 2020 Reimagined
10/22/2020
Chinook Therapeutics, Inc. (NASDAQ: KDNY), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced three poster presentations and one oral presentation at ASN’s Kidney Week 2020 Reimagined.
-
Chinook Therapeutics Announces Upcoming Data Presentations and Investor Conference Call During the American Society of Nephrology (ASN) Kidney Week 2020 Reimagined
10/9/2020
Chinook Therapeutics, Inc. (NASDAQ: KDNY), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced upcoming data presentations at ASN’s Kidney Week 2020 Reimagined from October 22-25, 2020.
-
Chinook Therapeutics Closes Merger with Aduro Biotech and Completes $115 Million Private Placement Financing
10/5/2020
Combined Company Will H ave Over $275 Million in Operating Capital and Trade on Nasdaq under the Ticker Symbol “KDNY” VANCOUVER, British Columbia and SEATTLE, Oct. 05, 2020 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ: KDNY), a clinical-stage biotechnology company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced the closing of its merger with Aduro Biotech, Inc. and $115 million priva
-
BioSpace Global Roundup, Aug. 20
8/20/2020
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines. -
Chinook Therapeutics Announces $106 Million Private Placement Financing to Advance Precision Medicines for Kidney Disease
8/18/2020
Chinook Therapeutics, Inc., a privately held clinical-stage biotechnology company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced a $106 million private placement financing,
-
BioSpace Global Roundup, June 4
6/4/2020
Biopharma and life sciences companies from across the globe provide updates on their pipelines and businesses. -
Aduro Biotech and Chinook Therapeutics Announce Definitive Merger Agreement
6/2/2020
– Combined Company Will Operate as Chinook Therapeutics and Advance Pipeline of Clinical-Stage Programs in Kidney Diseases, Led by Atrasentan and BION-1301 in IgA Nephropathy – Combined Company Will be Well-Funded With Cash Position of ~$200 Million Expected at Closing, Including $25 Million in Additional Investment Committed by Chinook’s Existing Investors – Multiple Clinical and Regulatory Pipeline Milestones Planned for Combined Company Over the Next 12-18 Months – Companies to H
-
When the transaction is completed, the combined company is expected to have about $200 million in cash, cash equivalents and marketable securities at closing.
-
Chinook Therapeutics to Present at the Jefferies Virtual Healthcare Conference
5/27/2020
Chinook Therapeutics, Inc. (“Chinook”), a privately held clinical-stage biotechnology company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that Eric Dobmeier, President and Chief Executive Officer, will present an overview of the company and its pipeline at the Jefferies Virtual Healthcare Conference at 3:30 p.m. EDT on Wednesday, June 3, 2020.